L3VLUP
ProSign in

EDIT · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EDITAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EDIT
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterEDITAMGN
Q3 20205 holders, $378m16 holders, $16.3bn
Q4 20206 holders, $969m19 holders, $14.0bn
Q1 20217 holders, $498m16 holders, $14.5bn
Q2 20216 holders, $540m23 holders, $13.8bn
Q3 20215 holders, $349m24 holders, $11.6bn
Q4 20215 holders, $178m21 holders, $10.4bn
Q1 20226 holders, $86m23 holders, $9.9bn
Q2 20226 holders, $41m28 holders, $9.7bn
Q3 20225 holders, $42m21 holders, $7.9bn
Q4 20225 holders, $29m24 holders, $9.3bn
Q1 20233 holders, $20m22 holders, $8.4bn
Q2 20234 holders, $47m26 holders, $7.4bn
Q3 20234 holders, $44m26 holders, $8.7bn
Q4 20233 holders, $21m24 holders, $8.4bn
Q1 20242 holders, $7.0m25 holders, $6.7bn
Q2 20243 holders, $6.3m20 holders, $8.0bn
Q3 20242 holders, $3.5m21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 2025none listed holders, n.a.25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 20261 holders, $12m23 holders, $24.9bn
EDIT

Editas Medicine Inc

Holders
2
Reported value
$3.5m
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
21
Reported value
$8.8bn
Buyers
16
Sellers
5

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 21 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EDIT (0)

None.

Only AMGN (19)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →